How semaglutide activates GLP-1 receptors: the mechanism
A long-acting copy of a natural gut hormone — engineered to last about a week and act on three different systems at once.
TL;DR
- Semaglutide is a GLP-1 receptor agonist (in plain English: a molecule that switches on the same receptors a natural gut hormone uses).
- It works through three pathways: it slows stomach emptying, signals fullness to the brain, and improves insulin response after meals.
- The branded versions — Ozempic for diabetes and Wegovy for weight management — are FDA-approved. Compounded semaglutide is not FDA-approved.
What it is
Semaglutide is a synthetic peptide modeled on GLP-1 (glucagon-like peptide-1). GLP-1 is a hormone the gut releases after meals. The natural version breaks down within minutes. Semaglutide is engineered with structural modifications that protect it from breakdown enzymes and let it bind to a transport protein in the bloodstream. The result is a molecule with a half-life of about one week (Knudsen and Lau, Frontiers in Endocrinology, 2019).
How it works
Think of GLP-1 as a fullness signal the body sends after a meal. Semaglutide is a longer-lasting copy of that signal.
When semaglutide is injected, it binds to GLP-1 receptors in several places. In the stomach, it slows how fast food empties — meals stay full longer. In the brain, it acts on areas that control appetite and meal size. In the pancreas, it boosts insulin release after meals and lowers glucagon, the hormone that raises blood sugar (Wilding et al., New England Journal of Medicine, 2021).
About 7 in 10 people on semaglutide notice changes in appetite within the first month. The slow titration schedule exists because turning all three of those pathways on at once tends to cause side effects.
Who asks about it
People usually arrive at semaglutide after reading about Ozempic or Wegovy. The follow-up question is what semaglutide is actually doing in the body. That is what this post answers.
What the research says
The largest published trials are STEP and SUSTAIN. They tracked semaglutide in chronic weight management and type 2 diabetes (Wilding et al., 2021). The mechanism story across the literature is consistent: appetite, gastric emptying, and insulin response all shift. Long-term outcome data is still building.
What to know before considering it
Semaglutide requires a prescription and a licensed clinician evaluation. Side effects in the published literature include nausea, vomiting, constipation, and injection-site reactions. Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, February 2026). The compounded version is prepared by state-licensed 503A pharmacies from FDA-approved active pharmaceutical ingredients and is not itself FDA-approved.
The Halftime POV
The mechanism story for semaglutide is one of the cleanest in modern metabolic medicine. The honest part is that the same three pathways that make it useful are the ones that produce side effects. We treat both at once.
Related reading:
- GLP-1: what this gut hormone actually does
- Compounded semaglutide: what it is and how it differs from branded
- GLP-1 side effects in the published literature
FAQ
Q: How does semaglutide work? A: Semaglutide binds to GLP-1 receptors throughout the body. The result is slower stomach emptying, a stronger fullness signal in the brain, and better insulin response after meals. The combination reduces appetite over time.
Q: Is semaglutide the same as Ozempic? A: Ozempic is a brand of semaglutide approved by the FDA for type 2 diabetes. Wegovy is a brand of semaglutide approved by the FDA for chronic weight management. Compounded semaglutide is not FDA-approved.
Q: How long does semaglutide stay in the body? A: Semaglutide has a half-life of about one week, which is why it is dosed weekly. The structural modifications that extend its half-life are what make once-weekly dosing possible.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
- Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 2019.
